GADECCU 2022 Guideline for the treatment of Ulcerative Colitis. Adaptation and updating of the GETECCU 2020 Guideline

被引:3
作者
Fuxman, Claudia [1 ]
Sicilia, Beatriz [2 ]
Linares, Maria Eugenia [3 ]
Garcia-Lopez, Santiago [4 ]
Sueyro, Ramiro Gonzalez [5 ]
Gonzalez-Lamac, Yago [6 ]
Zabana, Yamile [7 ]
Hinojosa, Joaquin [8 ]
Acosta, Manuel Barreiro -de [9 ]
Balderramo, Domingo [10 ]
Balfour, Deborah [11 ]
Bellicoso, Maricel [12 ]
Daffra, Pamela [13 ]
Morelli, Daniela [14 ]
Orsi, Marina [15 ]
Rausch, Astrid [16 ]
Ruffinengo, Orlando [17 ]
Toro, Martin [11 ]
Sambuelli, Alicia [18 ]
Novillo, Abel [19 ]
Gomollon, Fernando [20 ]
Paula, Juan Andres De [5 ]
机构
[1] Hosp Univ Fdn Favaloro, Serv Gastroenterol, Buenos Aires, Argentina
[2] Hosp Univ Burgos, Serv Aparato Digest, Unidad Enfermedad Inflamatoria Intestinal, Burgos, Spain
[3] Hosp Clin Jose San Martin, Serv Gastroenterol, Buenos Aires, Argentina
[4] Hosp Univ Miguel Servet, Serv Aparato Digest, Unidad Enfermedad Inflamatoria Intestinal, Inst Invest Sanit Aragon, Zaragoza, Spain
[5] Hosp Italiano Buenos Aires, Serv Gastroenterol, Buenos Aires, Argentina
[6] Hosp Univ Puerta Hierro, Serv Aparato Digest, Unidad Enfermedad Inflamatoria Intestinal, Madrid, Spain
[7] Hosp Univ Mutua Terrassa, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Serv Aparato Digest, Unidad Enfermedad Inflamatoria Intestinal, Barcelona, Spain
[8] Hosp Manise, Serv Aparato Digest, Unidad Enfermedad Inflamatoria Intestinal, Valencia, Spain
[9] Hosp Univ Santiago de Compostela, Serv Aparato Digest, Unidad Enfermedad Inflamatoria Intestinal, Santiago De Compostela, Spain
[10] Hosp Privado Univ Cordoba, Inst Univ Ciencias Biomed, Serv Gastroenterol, Cordoba, Argentina
[11] HIGEA Clin Gastroenterol, Unidad Enfermedades Inflamatorias, Mendoza, Argentina
[12] Area Gastroenterol, Inmunol Buenos Aires, Buenos Aires, Argentina
[13] Hosp Cent Mendoza, Serv Gastroenterol, Mendoza, Argentina
[14] Inst Efect Clin & Sanit, Dept Educ, Buenos Aires, Argentina
[15] Hosp Italiano Buenos Aires, Serv Gastroenterol Pediat, Buenos Aires, Argentina
[16] Hosp Britan Buenos Aires, Serv Gastroenterol, Buenos Aires, Argentina
[17] Hosp Prov Centenario, Serv Gastroenterol, Rosario, Argentina
[18] Hosp Bonorino Udaondo, Secc Enfermedades Inflamatorias Intestinales, Buenos Aires, Argentina
[19] Serv Gastroenterol, Sanat 9 Julio, San Miguel De Tucuman, Argentina
[20] Hosp Clin Univ Lozano Blesa, Zaragoza, Spain
来源
GASTROENTEROLOGIA Y HEPATOLOGIA | 2023年 / 46卷
关键词
Ulcerative colitis treatment; Clinical practice guideline; GRADE methodology; Argentina; INFLAMMATORY-BOWEL-DISEASE; FECAL MICROBIOTA TRANSPLANTATION; PLACEBO-CONTROLLED TRIAL; ORAL BECLOMETASONE DIPROPIONATE; ANTIBIOTIC COMBINATION THERAPY; RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND; MAINTENANCE THERAPY; 5-AMINOSALICYLIC ACID; INTRAVENOUS CYCLOSPORINE;
D O I
10.1016/j.gastrohep.2023.01.009
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Introduction: Ulcerative colitis (UC) is a chronic inflammatory disease that compromises the colon, affecting the quality of life of individuals of any age. In practice, there is a wide spectrum of clinical situations. The advances made in the physio pathogenesis of UC have allowed the development of new, more effective and safer therapeutic agents.Objectives: To update and expand the evaluation of the efficacy and safety of relevant treat-ments for remission induction and maintenance after a mild, moderate or severe flare of UC.Recipients: Gastroenterologists, coloproctologists, general practitioners, family physicians and others health professionals, interested in the treatment of UC. Methodology: GADECCU authorities obtained authorization from GETECCU to adapt and update the GETECCU 2020 Guide for the treatment of UC. Prepared with GRADE methodology. A team was formed that included authors, a panel of experts, a nurse and a patient, methodological experts, and external reviewers. GRADE methodology was used with the new information.Results: A 118-page document was prepared with the 44 GADECCU 2022 recommendations, for different clinical situations and therapeutic options, according to levels of evidence. A section was added with the new molecules that are about to be available. Conclusions: This guideline has been made in order to facilitate decision-making regarding the treatment of UC, adapting and updating the guide prepared by GETECCU in the year 2020.(c) 2023 Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:S1 / S56
页数:56
相关论文
共 249 条
[161]   Infliximab in moderately severe glucocorticoid resistant ulcerative colitis:: a randomised controlled trial [J].
Probert, CSJ ;
Hearing, SD ;
Schreiber, S ;
Kühbacher, T ;
Ghosh, S ;
Arnott, IDR ;
Forbes, A .
GUT, 2003, 52 (07) :998-1002
[162]   Temporal Trends in the epidemiology of Inflammatory Bowel Diseases in the public healthcare system in Brazil: A large population-based study [J].
Quaresma, A. B. ;
Damiao, A. O. M. C. ;
Coy, C. S. R. ;
Magro, D. O. ;
Valverde, D. A. ;
Panaccione, R. ;
Coward, S. B. ;
Ng, S. C. ;
Kaplan, G. G. ;
Kotze, P. G. .
JOURNAL OF CROHNS & COLITIS, 2021, 15 :S079-S080
[163]   A meta-analysis of antibiotic therapy for active ulcerative colitis [J].
Rahimi, Roja ;
Nikfar, Shekoufeh ;
Rezaie, Ali ;
Abdollahi, Mohammad .
DIGESTIVE DISEASES AND SCIENCES, 2007, 52 (11) :2920-2925
[164]  
RANZI T, 1989, LANCET, V2, P97
[165]   Medical management of left-sided ulcerative colitis and ulcerative proctitis: Critical evaluation of therapeutic trials [J].
Regueiro, Miguel ;
Loftus, Edward V., Jr. ;
Steinhart, A. Hillary ;
Cohen, Russell D. .
INFLAMMATORY BOWEL DISEASES, 2006, 12 (10) :979-994
[166]   Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension [J].
Reinisch, Walter ;
Gibson, Peter R. ;
Sandborn, William J. ;
Feagan, Brian G. ;
Strauss, Richard ;
Johanns, Jewel ;
Padgett, Lakshmi ;
Adedokun, Omoniyi J. ;
Colombel, Jean-Frederic ;
Collins, Judith ;
Rutgeerts, Paul ;
Tarabar, Dino ;
Marano, Colleen .
JOURNAL OF CROHNS & COLITIS, 2018, 12 (09) :1053-1066
[167]   Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial [J].
Reinisch, Walter ;
Sandborn, William J. ;
Hommes, Daniel W. ;
D'Haens, Geert ;
Hanauer, Stephen ;
Schreiber, Stefan ;
Panaccione, Remo ;
Fedorak, Richard N. ;
Tighe, Mary Beth ;
Huang, Bidan ;
Kampman, Wendy ;
Lazar, Andreas ;
Thakkar, Roopal .
GUT, 2011, 60 (06) :780-787
[168]   Oral beclomethasone dipropionate in patients with mild to moderate ulcerative colitis: A dose-finding study [J].
Rizzello, F ;
Gionchetti, P ;
Galeazzi, R ;
Novelli, G ;
Valpiani, D ;
D'Arienzo, F ;
Manguso, F ;
Castiglione, G ;
Varoli, G ;
Campieri, M .
ADVANCES IN THERAPY, 2001, 18 (06) :261-271
[169]   Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study [J].
Rizzello, F ;
Gionchetti, P ;
D'Arienzo, A ;
Manguso, F ;
Di Matteo, G ;
Annese, V ;
Valpiani, D ;
Casetti, T ;
Adamo, S ;
Prada, A ;
Castiglione, GN ;
Varoli, G ;
Campieri, M .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (06) :1109-1116
[170]   Longer term outcome of steroid refractory ulcerative colitis treated with intravenous cyclosporine without subsequent oral cyclosporine maintenance therapy [J].
Rolny, P ;
Sadik, R .
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2002, 17 (02) :67-69